Patents Examined by Elly-Gerald Stoica
  • Patent number: 11845792
    Abstract: This application provides, inter alia, antibodies or antigen-binding fragments thereof, targeting cell surface GRP78 expressed on tumor cells, tumor endothelial cells, and tumor initiating cancer cells. These anti-GRP78 antibodies, or antigen-binding fragments thereof, have a high affinity for GRP78 and are less immunogenic compared to their unmodified parent antibodies in a given species, e.g., a human, and function to inhibit GRP78. Importantly, these isolated novel antibodies and antigen-binding fragments thereof, attenuate PI3K signaling and promote apoptosis in tumor cells, while leaving normal cells unaffected. The antibodies and antigen-binding fragments are useful for UPR-targeted cancer therapeutic treatments.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: December 19, 2023
    Assignee: University of Southern California
    Inventors: Parkash Gill, Ren Liu, Amy Lee
  • Patent number: 11839644
    Abstract: Disclosed are methods of treating pain in a mammal, which may include the step of administering human growth hormone to a mammal in need thereof The pain treated by the disclosed methods may be of a type caused by inflammation induced mechanical and/or thermal hypersensitivity, and may include, for example, a pain type resulting from one or more conditions selected from peripheral injury pain, post-operative pain, cutaneous inflammation, cutaneous incision, muscle incision, or chronic pain. Disease states in which the disclosed methods may be used include fibromyalgia, sickle cell anemia, epidermolysis bullosa, erythromelalgia, complex regional pain syndrome, or generalized muscle pain.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: December 12, 2023
    Inventors: Michael P. Jankowski, Xiaohua Liu, John Barns Rose
  • Patent number: 11834492
    Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., an IL-10 trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion protein, or an expression vector encoding for the fusion proteins, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: December 5, 2023
    Assignee: EPICENTRX, INC.
    Inventors: Christopher Larson, Tony R. Reid, Bryan T. Oronsky
  • Patent number: 11826402
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: November 28, 2023
    Assignees: Astellas Pharma Inc., TRON-Translationale Onkologie an der Universitatsm
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • Patent number: 11827712
    Abstract: Provided are specific binding molecules, or fragments thereof, that bind to an epitope of IL13R?2, a receptor polypeptide preferentially found on the surface of cancer cells rather than healthy cells. Exemplary specific binding molecules are bispecific binding molecules that comprise a fragment of an IL13R?2 binding molecule and a peptide providing a second function providing a signaling function of the signaling domain of a T cell signaling protein, a peptide modulator of T cell activation, or an enzymatic component of a labeling system. Also provided are polynucleotides encoding such a specific binding molecule (e.g., bispecific binding molecule), vectors, host cells, pharmaceutical compositions and methods of preventing, treating or ameliorating a symptom associated with a cancer disease such as a solid tumor disease (e.g., glioblastoma multiforme).
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: November 28, 2023
    Assignee: The University of Chicago
    Inventors: Irina V. Balyasnikova, Maciej S. Lesniak
  • Patent number: 11806398
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: November 7, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Kelly Frye, Susan Kautz
  • Patent number: 11802145
    Abstract: A recombinant fusion protein comprising 1) TGF?R2, or a fragment thereof, capable of binding to TGF?, and 2) an antibody, or an antigen-binding fragment thereof, that binds to PD-1. Also disclosed are a polynucleotide encoding the recombinant fusion protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over expression of TGF? and/or PD-1 using the recombinant protein.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: October 31, 2023
    Assignee: Nanjing Leads Biolabs Co., Ltd.
    Inventors: Xiaoqiang Kang, Xiao Huang
  • Patent number: 11802163
    Abstract: Nucleic acid constructs encoding a chimeric antigen receptor (CAR) and a truncated human epidermal growth factor receptor (huEGFRt) are described. The encoded CARs include a tumor antigen-specific monoclonal antibody, such as a glypican-3 (GPC3)-specific, a GPC2-specific or a mesothelin-specific monoclonal antibody, fused to a CD8? hinge region, a CD8? transmembrane region, a 4-1BB co-stimulatory domain and a CD3? signaling domain. Isolated host cells, such as isolated T cells that co-express the disclosed CARs and huEGFRt are also described. T cells transduced with the disclosed CAR constructs can be used for cancer immunotherapy.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: October 31, 2023
    Assignee: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Mitchell Ho, Nan Li, Dan Li
  • Patent number: 11771720
    Abstract: The present invention relates to anticancer extracellular vesicles, a preparation method therefor, and an anticancer composition comprising same. Immune-tolerized extracellular vesicles containing LDHB and PGC-1? of the present invention provide cancer treatment, suppression of cancer metastasis, and cancer prevention technologies by normalizing cancer cell-specific aerobic glycolysis energy metabolic pathway in which lactate and hydrogen ions, which form a tumor microenvironment favorable for immune evasion, proliferation, metastasis and invasion of cancer cells, are produced, thereby enabling tumors to be effectively removed by means of the immune system of a patient.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: October 3, 2023
    Assignee: STEMMEDICARE CO., LTD.
    Inventor: Jang Ho Lee
  • Patent number: 11773158
    Abstract: Compositions, methods, and uses of recombinant IL-8 antibody, fragment thereof or single chain variable fragment (scFv) having high affinity to IL-8 to target tumor-expressed or endogenous IL-8 are presented. Preferably, the recombinant IL-8 antibody or scFv fragment includes a VH segment comprising a first amino acid sequence selected from SEQ ID NO. 1-15, 31-32, and/or a VL segment comprising a second amino acid sequence selected from SEQ ID NO. 16-30, 33-34. The recombinant IL-8 antibody or scFv fragment can be formulated as pharmaceutical compositions to administer to a patient having a tumor to reduce metastasis of the tumor, reduce immune suppression in the tumor microenvironment or reduce Th2 mediated immune response.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: October 3, 2023
    Assignee: NantBio, Inc.
    Inventors: Patrick Soon-Shiong, Kayvan Niazi, Shiho Tanaka, Jon Thomas Van Lew, Clifford Anders Olson, Philip T. Liu
  • Patent number: 11759508
    Abstract: The present invention relates to antigen-based immunotherapy, in particular cancer immunotherapy. In particular, the present invention provides antigenic peptides, which are distinct from, but have amino acid similarity to, especially share the same core sequence with epitopes of human tumor antigens. The present invention further provides immunogenic compounds, nanoparticles, cells and pharmaceutical compositions comprising such antigenic peptides and nucleic acids encoding such antigenic peptides.
    Type: Grant
    Filed: May 2, 2022
    Date of Patent: September 19, 2023
    Assignee: ENTEROME S.A.
    Inventors: Laurent Chene, Francesco Strozzi, Joao Gamelas Magalhaes, Guillaume Kulakowski
  • Patent number: 11752096
    Abstract: The present disclosure provides compositions and methods for intra-articular delivery of anti-CSF1R antibodies to a tissue that is impacted by a disease that is treatable with CSF1/CSF1R inhibition and/or that expresses CSF1R. It was conventional knowledge that the intra-articular dwell time of proteins in joints is typically a few hours or less. The present disclosure shows, however, that intra-articular delivery of an anti-CSF1R antibody can lead to sustained exposure and pharmacologic activity of the antibody in the joints far beyond a few hours, providing an effective means for targeted and extended delivery of the therapeutic agent.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: September 12, 2023
    Assignee: AmMax Bio, Inc.
    Inventors: Laman Alani, Kirk William Johnson, Michael Huang, Chung-Chiang Hsu
  • Patent number: 11744862
    Abstract: Methods for treating AL amyloidosis using chimeric antigen receptors targeting CS1 are described.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: September 5, 2023
    Assignee: City of Hope
    Inventors: Xiuli Wang, Stephen J. Forman
  • Patent number: 11744860
    Abstract: The present invention relates to a method for producing en NKT cell ligand-pulsed human CD14 positive cell that activates NKT cells and strongly induces proliferation, IFN-? production, and/or cytotoxic activity of NKT cells. More specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and GM-CSF and substantially free of IL-4. In addition, the present invention relates to a method for producing an NKT cell ligand-pulsed human CD14 positive cell line and, specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and substantially free of GM-CSF and IL-4. The present invention also relates to a cell preparation containing an NKT cell ligand-pulsed human CD14 positive cell or an NKT cell ligand-pulsed human CD14 positive cell line and pharmaceutical use thereof.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: September 5, 2023
    Assignees: RIKEN, AMBICION CO., LTD.
    Inventors: Masaru Taniguchi, Tomokuni Shigeura, Minako Aihara, Keigo Hanada
  • Patent number: 11738051
    Abstract: The present invention provides a nucleotide sequence for encoding CAR, a ROBO1 CAR-NK cell of expressing the CAR, and preparation and application thereof. The ROBO1 CAR-NK cell provided by the present invention can specifically kill tumor cells by using ROBO1 antibody for the construction of CAR-NK cells and using ROBO1 molecules as target antigens. It can be used as a therapeutic agent for tumor diseases, for the treatment of tumor with highly expressing of ROBO1, without harmful phenomena such as cytokine release syndrome, thus providing new treatments for the tumors which are ineffective in traditional surgery, chemotherapy and radiotherapy. It has lower toxicity, higher safety and better specific lysis activity compared with ROBO1 CAR-T cell.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: August 29, 2023
    Inventors: Huashun Li, Kunkun Han, Baolei Wang, Baoyong Ren
  • Patent number: 11740244
    Abstract: The present invention relates to methods and kits for detection protein-protein interactions.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: August 29, 2023
    Inventors: Stéphanie Cabantous, Faten Koraïchi, Gilles Favre
  • Patent number: 11738050
    Abstract: This disclosure describes a compound that binds to fibroblast activation protein alpha (FAP), compositions including the compound, and methods of using the compound, and compositions. In some embodiments, the compound is a monoclonal antibody that binds FAP. The compound may be used, for example, as a research tool, in clinical imaging, as a diagnostic agent, or as a therapeutic agent.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: August 29, 2023
    Inventors: Aaron M. LeBeau, Hallie M. Hintz
  • Patent number: 11739156
    Abstract: The present invention discloses novel methods, compositions, and uses thereof for removing or overcoming immunosuppression. More specifically, the methods and compositions disclosed herein target effector Treg cells by modulating ST2 and/or IL-33 signaling using pharmaceutical inhibitors and/or genetic ablation, whereby the levels and/or activities of effector Treg cells in a tumor microenvironment are inhibited, and the infiltration of effector CD8+ cytotoxic T cells into tumor microenvironment increases. As a result, tumor growth is inhibited and tumor volume is reduced. The present invention also provides methods for identifying and isolating effector Treg cells in a population of heterogeneous cells.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: August 29, 2023
    Assignee: The Broad Institute, Inc. Massachusetts Institute of Technology
    Inventors: Amy Li, Rebecca H. Herbst, Aviv Regev, Tyler Jacks, David Canner
  • Patent number: 11739297
    Abstract: The present disclosure pertains to immune cells comprising chimeric antigen receptors (CARs) and methods of using immune cells comprising CARs.
    Type: Grant
    Filed: September 16, 2021
    Date of Patent: August 29, 2023
    Assignee: Carisma Therapeutics Inc.
    Inventors: Michael Klichinsky, Nicholas G. Minutolo, Nicholas R. Anderson
  • Patent number: 11732050
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: August 22, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro